Lyell Immunopharma, Inc. — Director's Dealing 2025

Apr 2, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-03-31

Reporting Person: BRAWLEY OTIS W (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-31	Common Stock	P	35640	$0.56	Acquired	35640	Direct